Evidence map›Paper›PMID 34757622›Full record

ReviewFEBS letters2021

Neurological pathophysiology of SARS-CoV-2 and pandemic potential RNA viruses: a comparative analysis.

Nikhil Chakravarty, Thrisha Senthilnathan, Sophia Paiola, Priya Gyani, Sebastian Castillo Cario, Estrella Urena, Akash Jeysankar, Prakash Jeysankar, Joseph Ignatius Irudayam, Sumathi Natesan Subramanian and 5 more

Open access · bronzeAbstract readComparative StudyReview
PubMed Full text at PMC Publisher
In one paragraph

Review in FEBS letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. An open trial of biofeedback for long COVID.Journal of psychosomatic research · 2024
    Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Nikhil ChakravartyDepartment of Epidemiology, University of California, Los Angeles, CA, USA.
Thrisha SenthilnathanDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Sophia PaiolaDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Priya GyaniDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Sebastian Castillo CarioDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Estrella UrenaDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Akash JeysankarDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Prakash JeysankarDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Joseph Ignatius IrudayamDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Sumathi Natesan SubramanianDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Helen LavretskyJane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
Shantanu JoshiDepartment of Neurology, University of California, Los Angeles, CA, USA.
Gustavo GarciaDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Arunachalam RamaiahDepartment of Ecology and Evolutionary Biology, University of California, Irvine, CA, USA.ORCID 0000-0003-3573-6141
Vaithilingaraja ArumugaswamiDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
University of California, Los Angeles · USCalifornia NanoSystems Institute · USUniversity of California, Irvine · US

Funding

Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicityR01DK132735 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARUMUGASWAMI, VAITHILINGARAJA, DEB, ARJUN · 2021 to 2023
$6.0M
Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infectionR01EY032149 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Vaithilingaraja Arumugaswami, Ashok Kumar · 2021 to 2026
$2.8M
Broad Stem Cell Research Center OCRC #20-15National Institute of Health 1R01DK132735-01National Institute of Health 1R01EY032149-01NEI NIH HHS R01 EY032149NIDDK NIH HHS R01 DK132735UCLA W.M. Keck Foundation COVID-19 Research Award
6 · The paper itself

Abstract

SARS-CoV-2 has infected hundreds of millions of people with over four million dead, resulting in one of the worst global pandemics in recent history. Neurological symptoms associated with COVID-19 include anosmia, ageusia, headaches, confusion, delirium, and strokes. These may manifest due to viral entry into the central nervous system (CNS) through the blood-brain barrier (BBB) by means of ill-defined mechanisms. Here, we summarize the abilities of SARS-CoV-2 and other neurotropic RNA viruses, including Zika virus and Nipah virus, to cross the BBB into the CNS, highlighting the role of magnetic resonance imaging (MRI) in assessing presence and severity of brain structural changes in COVID-19 patients. We present new insight into key mutations in SARS-CoV-2 variants B.1.1.7 (P681H) and B.1.617.2 (P681R), which may impact on neuropilin 1 (NRP1) binding and CNS invasion. We postulate that SARS-CoV-2 may infect both peripheral cells capable of crossing the BBB and brain endothelial cells to traverse the BBB and spread into the brain. COVID-19 patients can be followed up with MRI modalities to better understand the long-term effects of COVID-19 on the brain.

Indexed as

Blood-Brain BarrierHenipavirus InfectionsNipah VirusSARS-CoV-2Zika VirusZika Virus InfectionCOVID-19HumansMutationblood-brain barrierbraincentral nervous systemCOVID-19magnetic resonance imagingneuropathophysiologyRNA virusesSARS-CoV-2

Identifiers

PMID34757622
PMCPMC8652524
OpenAlexW3214650646

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.